Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 7/2020

Open Access 01-07-2020 | Glucocorticoid | Original Article

Low bone mineral density is associated with hypogonadism and cranial irradiation in male childhood cancer survivors

Authors: S. Isaksson, K. Bogefors, K. Åkesson, I. Øra, L. Egund, J. Bobjer, I. Leijonhufvud, A. Giwercman

Published in: Osteoporosis International | Issue 7/2020

Login to get access

Abstract

Summary

We investigated if bone mineral density was related to testosterone deficiency and/or previous cancer treatment in men who were childhood cancer survivors. Men with untreated testosterone deficiency or previous treatment with cranial irradiation were at increased risk of impaired bone health. Prevention of osteoporosis should be considered in their follow-up.

Introduction

Childhood cancer survivors (CCS) are at increased risk of hypogonadism. Reduced bone mineral density (BMD) has been reported in CCS but it is unclear whether this is due to hypogonadism or a direct effect of cancer therapy. This study investigated BMD in CCS, and association with hypogonadism, previous treatment and cancer type.

Methods

Investigation of 125 CCS (median age 33.7 at inclusion; 9.6 at diagnosis) and 125 age-matched population controls. Serum testosterone and luteinizing hormone were assayed and BMD at total hip and lumbar spine L1–L4 measured. The mean difference in BMD (g/cm2; 95% CI) between CCS and controls was analysed. Odds ratios (OR; 95% CI) for low BMD were also calculated.

Results

Overall, BMD in the CCS cohort did not significantly differ from controls. However, compared with eugonadal CCS, the CCS with untreated hypogonadism had lower BMD at the hip (mean difference − 0.139 (− 0.210; − 0.067); p < 0.001) and spine (− 0.102 (− 0.174; − 0.030); p = 0.006). They also had a higher risk of low hip BMD (OR 4.1 (1.3; 14); p = 0.018). CCS treated with cranial irradiation also had lower BMD (hip − 0.076 (− 0.133; − 0.019); p = 0.009; spine − 0.071 (− 0.124; − 0.018); p = 0.009) compared with controls. The latter associations remained statistically significant after adjustment for hypogonadism.

Conclusions

CCS with hypogonadism or previously treated with cranial irradiation are at increased risk of impaired bone health. Prevention of osteoporosis should be considered as an important part in future follow-up of these men.
Appendix
Available only for authorised users
Literature
1.
Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA, Group EW (2009) Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45:992–1005CrossRef
2.
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis & Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. Jama 285:785–795CrossRef
3.
Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194CrossRef
4.
Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung M, Miller PD, Yuen CK (2004) Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 26:15–28CrossRef
5.
Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL (2013) Clinical ascertainment of health outcomes among adults treated for childhood cancer. Jama 309:2371–2381CrossRef
6.
7.
Kang MJ, Lim JS (2013) Bone mineral density deficits in childhood cancer survivors: pathophysiology, prevalence, screening, and management. Korean J Pediatr 56:60–67CrossRef
8.
Siegel DA, Claridy M, Mertens A, George E, Vangile K, Simoneaux SF, Meacham LR, Wasilewski-Masker K (2017) Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors. Pediatr Blood Cancer 64(9): p 8
9.
Holmes SJ, Whitehouse RW, Clark ST, Crowther DC, Adams JE, Shalet SM (1994) Reduced bone mineral density in men following chemotherapy for Hodgkin’s disease. Br J Cancer 70:371–375CrossRef
10.
Chaiban J, Muwakkit S, Arabi A, Jomaa L, Daouk LO, El-Rassi R, Abboud M, El-Hajj Fuleihan G (2009) Modeling pathways for low bone mass in children with malignancies. J Clin Densitom 12:441–449CrossRef
11.
Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, Sklar C (1998) Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 20:241–245CrossRef
12.
Polgreen LE, Petryk A, Dietz AC et al (2012) Modifiable risk factors associated with bone deficits in childhood cancer survivors. BMC Pediatr 12:40CrossRef
13.
Romerius P, Stahl O, Moell C, Relander T, Cavallin-Stahl E, Wiebe T, Giwercman YL, Giwercman A (2009) Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab 94:4180–4186CrossRef
14.
Isaksson S, Bogefors K, Akesson K, Egund L, Bobjer J, Leijonhufvud I, Giwercman A (2017) Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality. Andrology 5:898–904CrossRef
15.
Isaksson S, Bogefors K, Stahl O et al (2018) High risk of hypogonadism in young male cancer survivors. Clin Endocrinol 88:432–441CrossRef
16.
17.
Callreus M, McGuigan F, Akesson K (2014) Country-specific young adult dual-energy X-ray absorptiometry reference data are warranted for T-score calculations in women: data from the peak-25 cohort. J Clin Densitom 17:129–135CrossRef
18.
Unnanuntana A, Gladnick BP, Donnelly E, Lane JM (2010) The assessment of fracture risk. J Bone Joint Surg Am 92:743–753CrossRef
19.
Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409–419CrossRef
20.
Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, Neglia JP, Sklar CA, Kaste SC, Hudson MM, Diller LR, Stovall M, Donaldson SS, Robison LL (2014) The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the childhood cancer survivor study. Pediatr Blood Cancer 61:53–67CrossRef
21.
Mandel K, Atkinson S, Barr RD, Pencharz P (2004) Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 22:1215–1221CrossRef
22.
Boot AM, van den Heuvel-Eibrink MM, Hahlen K, Krenning EP, de Muinck Keizer-Schrama SM (1999) Bone mineral density in children with acute lymphoblastic leukaemia. Eur J Cancer 35:1693–1697CrossRef
23.
van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, Krenning EP, de Muinck Keizer-Schrama SM (2002) Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 141:204–210CrossRef
24.
Holzer G, Krepler P, Koschat MA, Grampp S, Dominkus M, Kotz R (2003) Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg (Br) 85:231–237CrossRef
25.
Marcucci G, Beltrami G, Tamburini A et al (2019) Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol 30:908–920CrossRef
26.
Gurney JG, Kaste SC, Liu W, Srivastava DK, Chemaitilly W, Ness KK, Lanctot JQ, Ojha RP, Nottage KA, Wilson CL, Li Z, Robison LL, Hudson MM (2014) Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 61:1270–1276CrossRef
27.
Barake M, Klibanski A, Tritos NA (2014) Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99:852–860CrossRef
28.
Gaffney CD, Pagano MJ, Kuker AP, Stember DS, Stahl PJ (2015) Osteoporosis and low bone mineral density in men with testosterone deficiency syndrome. Sexual Med Rev 3:298–315CrossRef
29.
Kacker R, Conners W, Zade J, Morgentaler A (2014) Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J Urol 191:1072–1076CrossRef
30.
Howell SJ, Radford JA, Adams JE, Shalet SM (2000) The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol 52:609–616CrossRef
31.
Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM, Barnes N, Armstrong GT, Krasin MJ, Srivastava DK, Pui CH, Merchant TE, Kun LE, Gajjar A, Hudson MM, Robison LL, Sklar CA (2015) Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude lifetime cohort study. J Clin Oncol 33:492–500
32.
Tritos NA (2017) Focus on growth hormone deficiency and bone in adults. Best Pract Res Clin Endocrinol Metab 31:49–57CrossRef
33.
Chemaitilly W, Sklar C (2009) Disturbances of Growth and Pubertal Development in Childhood Cancer Survivors. In: Yeung S-C, Escalante C P, Gagel R F Medical care of cancer patients, 1st edn. B C Decker inc, Shelton, Connecticut, p 671
34.
Binkovitz LA, Henwood MJ (2007) Pediatric DXA: technique and interpretation. Pediatr Radiol 37:21–31CrossRef
35.
den Hoed MA, Klap BC, te Winkel ML et al (2015) Bone mineral density after childhood cancer in 346 long-term adult survivors of childhood cancer. Osteoporos Int 26:521–529CrossRef
36.
Arikoski P, Komulainen J, Voutilainen R, Riikonen P, Parviainen M, Tapanainen P, Knip M, Kroger H (1998) Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 20:234–240CrossRef
37.
Kaste SC, Jones-Wallace D, Rose SR, Boyett JM, Lustig RH, Rivera GK, Pui CH, Hudson MM (2001) Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 15:728–734CrossRef
38.
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 63:280–293CrossRef
39.
Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, Erwin PJ, Montori VM (2006) Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 91:2011–2016CrossRef
40.
Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R (2008) Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20:378–387CrossRef
41.
Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D (2010) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 58:1134–1143CrossRef
42.
Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, Lenzi A, Migliaccio S (2012) Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15:96–102CrossRef
43.
Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS, Endocrine S (2012) Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:1802–1822CrossRef
Metadata
Title
Low bone mineral density is associated with hypogonadism and cranial irradiation in male childhood cancer survivors
Authors
S. Isaksson
K. Bogefors
K. Åkesson
I. Øra
L. Egund
J. Bobjer
I. Leijonhufvud
A. Giwercman
Publication date
01-07-2020
Publisher
Springer London
Published in
Osteoporosis International / Issue 7/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-020-05285-4

Other articles of this Issue 7/2020

Osteoporosis International 7/2020 Go to the issue

Correction

Correction to: Bone health in estrogen-free contraception

Original Article

Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment

Short Communication

Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia

Original Article

Targeted bone density testing for optimizing fracture prevention in Canada

Original Article

Accelerometer-based prediction of skeletal mechanical loading during walking in normal weight to severely obese subjects

Original Article

Introducing mobile fracture prevention services with DXA in Northern Scotland: a comparative study of three rural communities